The mechanistic imperative for pharmacogenomics

Pharmacogenomics

Volumn 9, Issue 7, 2008, Pages 801-803

  Dorn II, Gerald W ^a   Cresci, Sharon ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 5; GENOMIC DNA; GLUTAMINE; LEUCINE; NICOTINIC RECEPTOR; PLACEBO; PROPRANOLOL; DRUG;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; EDITORIAL; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LIFE EXPECTANCY; MORTALITY; NONHUMAN; PATENT; PHARMACODYNAMICS; PHARMACOGENOMICS; PROGNOSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; METABOLISM; METHODOLOGY; PHARMACOGENETICS;

HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; VARIATION (GENETICS);

EID: 49949093130     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.7.801     Document Type: Editorial

References (16)

1. Yancy CW: Heart failure in African Americans. Am. J. Cardiol. 96, 3i-12i (2005).
2. Kazius J, Wurdinger K, van IM, Kok J, Back T, Ijzerman AP: GPCR NaVa database: natural variants in human G protein-coupled receptors. Hum. Mutat. 29, 39-44 (2008).
3. Lefkowitz RJ: Seven transmembrane receptors: something old, something new. Acta Physiol. (Oxf) 190, 9-19 (2007).
4. Liggett SB, Cresci S, Kelly RJ et al.: A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure. Nat. Med. 14(5), 510-517 (2008).
5. Levy D, Kenchaiah S, Larson MG et al.: Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med. 347, 1397-1402 (2002).
6. Roger VL, Weston SA, Redfield MM et al.: Trends in heart failure incidence and survival in a community-based population. JAMA 292, 344-350 (2004).
7. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353, 2001-2007 (1999).
8. Fauchier L, Pierre B, de LA, Babuty D: Comparison of the beneficial effect of β-blockers on mortality in patients with ischaemic or non-ischaemic systolic heart failure: a meta-analysis of randomised controlled trials. Eur. J. Heart Fail. 9, 1136-1139 (2007).
9. Sleight P: Angiotensin II and trials of cardiovascular outcomes. Am. J. Cardiol. 89, 11A-16A (2002).
10. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB: Synergistic polymorphisms of β1- and α2C-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347, 1135-1142 (2002).
11. Bristow MR: Mechanistic and clinical nationales for using β-blockers in heart failure. J. Card. Fail. 6, 8-14 (2000).
12. Topol EJ, Frazer KA: The resequencing imperative. Nat. Genet. 39, 439-440 (2007).
13. Hung RJ, McKay JD, Gaborieau V et al.: A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452, 633-637 (2008).
14. Thorgeirsson TE, Geller F, Sulen P et al.: A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452, 638-642 (2008).
15. Amos CI, Wu X, Broderick P et al.: Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 40, 616-622 (2008).
16. Chanock SJ, Hunter DJ: Genomics: when the smoke clears. Nature 452, 537-538 (2008).